ELGN-2112 not checked

Elgan Pharma Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.”In the company’s words, NCT05904626 on ClinicalTrials.gov
Tested for
Intestinal Malabsorption (2 trials)
Main trialPhase 3
“The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.”In the company’s words, NCT05670951 on ClinicalTrials.gov

Other drugs for Intestinal Malabsorption

All 17 drugs for Intestinal Malabsorption

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Nov 2027 Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Phase 2Recruiting Jun 2027 Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow ELGN-2112

Following is part of Solo: you see every change to ELGN-2112 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in